Skip to main content
SpringerLink
Log in

Proteasome inhibitors induce growth inhibition and apoptosis in myeloma cell lines and in human bone marrow myeloma cells irrespective of chromosome 13 deletion

  • Original Paper
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Purpose

In this study, we investigated the effects of cell-permeable proteasome inhibitors MG-132, MG-262, PSI, and lactacystin on multiple myeloma cell lines OPM-2, U266, RPMI 8226-S, freshly isolated plasma cells with or without deletion of chromosome 13 from patients with multiple myeloma and plasma cell leukemia, and CD34+ human hematopoietic stem cells. The effects of proteasome inhibitors on cell cycle progression, cell growth, and apoptosis were determined.

Methods

MTT-assay was used to examine the cytotoxicity, and annexin-V staining to quantify apoptosis. Cell cycle analyses were performed using 7-ADD and Ki-67 staining by flow cytometry.

Results

PSI was the most potent proteasome inhibitor among those tested with a half maximal cytotoxicity (IC50) of 5.7 nM, followed by MG-262, MG-132, and lactacystin. Growth inhibition occurred irrespective of chromosome 13 status. Cell cycle arrest occurred in a dose- and time-dependent manner. Low, subapoptotic dosages led to a partial loss of Ki-67 antigen, whereas apoptotic dosages led to reduced Ki-67 levels. Apoptosis was partially dependent on activation of caspase-3, since Ac-DEVD-cho, a caspase-3 inhibitor, could reduce apoptosis significantly. The cytotoxicity of the four proteasome inhibitors tested was significantly lower in human hematopoietic stem cells than in myeloma cells.

Conclusions

Our results show that proteasome inhibitors induce time- and dose-dependent cell cycle alterations, growth inhibition, and apoptosis in human myeloma cells irrespective of chromosome 13 deletion.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1a–d.
Fig. 2.
Fig. 3a, b.
Fig. 4a–c.
Fig. 5a, b.
Fig. 6a, b.

Similar content being viewed by others

References

  • Adams J, Behnke M, Chen S, Cruickshank AA, Dick LR, Grenier L, Klunder JM, Ma YT, Plamondon L, Stein RL (1998) Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg Med Chem Lett 8:333–338

    Article  PubMed  Google Scholar 

  • Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S, Elliott PJ (1999) Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 59:2615–2622

    CAS  PubMed  Google Scholar 

  • Adams J, Palombella VJ, Eliott PJ (2000) Proteasome inhibition: a new strategy in cancer treatment. Invest New Drugs 18:109–121

    Article  CAS  PubMed  Google Scholar 

  • Blagosklonny MV, Wu GS, Omura S, El-Deiry WS (1996) Proteasome-dependent regulation of p21WAF1/CIP1 expression. Biochem Biophys Res Com 227:564–569

    Article  CAS  PubMed  Google Scholar 

  • Boyer SN, Wazer DE, Band V (1996) E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res 56:4620–4624

    CAS  PubMed  Google Scholar 

  • Casaccia-Bonnefil P, Tikoo R, Kiyokawa H, Friedrich V Jr, Chao MV, Koff A (1997) Oligodendrocyte precusor differentiation is preturbed in the absence of the cyclin-dependent kinase inhibitor p27Kip1. Genes Dev 11:2335–2346

    CAS  PubMed  Google Scholar 

  • Dick LR, Cruickshank AA, Grenier L, Melandri FD, Nunes SL, Stein RL (1996) Mechanistic studies on the inactivation of the proteasome by lactacystin: a central role for clasto-lactacystin beta-lactone. J Biol Chem 271:7273–7276

    CAS  PubMed  Google Scholar 

  • Dick LR, Cruikshank AA, Destree AT, Grenier L, McCormack TA, Melandri FD, Nunes SL, Palombella VJ, Parent LA, Plamondon L, Stein RL (1997) Mechanistic studies on the inactivation of the proteasome by lactacystin in cultured cells. J Biol Chem 272:182–188

    Article  PubMed  Google Scholar 

  • Domenech J, Georget MT, Gihana E, Colombat P, Bremond JL, Chassaigne M, Lamagnere JP, Binet C (1992) Evaluation of doxorubicin in combination with mafosfamide for in vitro elimination of myeloid and lymphoid tumor cells from human bone marrow. Bone Marrow Transplant 9:101–106

    CAS  Google Scholar 

  • Drexler HC (1997) Activation of the cell death program by inhibition of proteasome function. Proc Natl Acad Sci USA 94:855–860

    CAS  Google Scholar 

  • Endl E, Gerdes J (2000) Posttranslational modifications of the KI-67 protein coincide with two major checkpoints during mitosis. J Cell Physiol 182:371–380

    CAS  PubMed  Google Scholar 

  • Fujisawa T, Watanabe J, Akaboshi M, Ohno E, Kuramoto H (2001) Immunohistochemical study on VEGF expression in endometrial carcinoma—comparison with p53 expression, angiogenesis, and tumor histologic grade. J Cancer Res Clin Oncol 127:668–674

    CAS  PubMed  Google Scholar 

  • Fuse T, Tanikawa M, Nakanishi M, Ikeda K, Tada T, Inagaki H, Asai K, Kato T, Yamada K (2000) p27Kip1 expression by contact inhibition as a prognostic index of human glioma. J Neurochem 74:1393–1399

    Article  CAS  PubMed  Google Scholar 

  • Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H (1984) Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133:1710–1715

    CAS  PubMed  Google Scholar 

  • Ghielmini M, Colli E, Bosshard G, Pennella G, Geroni C, Torri V, D'Incalci M, Cavalli F, Sessa C (1998) Hematotoxicity on human bone marrow- and umbilical cord blood-derived progenitor cells and in vitro therapeutic index of methoxymorpholinyl-doxorubicin and its metabolites. Cancer Chemother Pharmacol 42:235–240

    Article  CAS  PubMed  Google Scholar 

  • Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, Anderson KC (2001) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61:3071–3076

    PubMed  Google Scholar 

  • Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, Munshi N, Dang L, Castro A, Palombella V, Adams J, Anderson KC (2002) NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 277:16639–16647

    Article  CAS  PubMed  Google Scholar 

  • King RW, Deshaies RJ, Peters JM, Kirschner MW (1996) How proteolysis drives the cell cycle. Science 274:1652–1659

    CAS  PubMed  Google Scholar 

  • Kitagawa H, Tani E, Ikemoto H, Ozaki I, NakanoA, Omura S (1999) Proteasome inhibitors induce mitochondria independent apoptosis in human glioma cells. FEBS Lett 443:181–186

    Article  CAS  PubMed  Google Scholar 

  • Komuro H, Kaneko S, Kaneko M, Nakanishi Y (2001) Expression of angiogenic factors and tumor progression in human neuroblastoma. J Cancer Res Clin Oncol 127:739–743

    CAS  PubMed  Google Scholar 

  • Kumeda SI, Deguchi A, Toi M, Omura S, Umezawa K (1999) Induction of G1 arrest and selective growth inhibition by lactacystin in human umbilical vein endothelial cells. Anticancer Res 19:3961–3968

    CAS  PubMed  Google Scholar 

  • Li B, Dou QP (2000) Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression. Proc Natl Acad Sci USA 97:3850–3855

    Article  CAS  PubMed  Google Scholar 

  • Machiels BM, Henfling ME, Gerards WL, Broers JL, Bloemendal H, Ramaekers FC, Schutte B (1997) Detailed analysis of cell cycle kinetics upon proteasome inhibition. Cytometry 28:243–252

    Article  CAS  PubMed  Google Scholar 

  • Maehara Y, Anai H, Tamada R, Sugimachi K (1987) The ATP assay is more sensitive than the succinate dehydrogenase inhibition test for predicting cell viability. Eur J Cancer Clin Oncol 23:273–276

    CAS  PubMed  Google Scholar 

  • Maki CG, Huibregtse JM, Howley PM (1996) In vivo ubiquitination and proteasome mediated degradation of p53. Cancer Res 56:2649–2654

    CAS  PubMed  Google Scholar 

  • Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, Munshi N, Treon SP, Anderson KC (2002a) Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood 99:4079–4086

    Article  CAS  PubMed  Google Scholar 

  • Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann TA, Treon SP, Munshi NC, Richardson PG, Hideshima T, Anderson KC (2002b) Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA 99:14374–14379

    Article  CAS  PubMed  Google Scholar 

  • Naujokat C, Sezer O, Zinke H, Leclere A, Hauptmann S, Possinger K (2000) Proteasome inhibitors induce caspase-dependent apoptosis and accumulation of p21 WAF1/Cip1 in human immature leukemic cells. Eur J Haematol 65:221–236

    Article  CAS  PubMed  Google Scholar 

  • Naujokat C, Hoffmann S (2002) Role and function of the 26S proteasome in proliferation and apoptosis. Lab Invest 82:965–980

    CAS  PubMed  Google Scholar 

  • Nawrocki ST, Bruns CJ, Harbison MT, Bold RJ, Gotsch BS, Abbruzzese JL, Elliott P, Adams J, McConkey DJ (2002) Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther 1:1243–1253

    CAS  PubMed  Google Scholar 

  • Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, Gareau Y, Griffin PR, Labelle M, Lazebnik YA (1995) Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 376:37–43

    CAS  PubMed  Google Scholar 

  • Niemöller K, Jakob C, Heider U, Zavrski I, Eucker J, Kaufmannn O, Possinger K, Sezer O (2003) Bone marrow angiogenesis and its correlation with other disease characteristics in multiple myeloma in stage I versus stage II-III. J Cancer Res Clin Oncol 129:234–238

    Google Scholar 

  • Orlowski RZ (1999) The ubiquitin-proteasome pathway in apoptosis. Cell Death Differ 6:303–313

    Article  CAS  PubMed  Google Scholar 

  • Orlowski M, Cardozzo C, Michaud C (1993) Evidence for the presence of five distinct proteolytic components in the pituitary multicatalytic proteinase complex. Properties of two components cleaving bonds on the carboxyl side of branched chain an small neutral amino acids. Biochemistry 32:1563–1572

    CAS  PubMed  Google Scholar 

  • Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, Yew PR, Draetta GF, Rolfe M (1995) Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin dependent kinase inhibitor p27. Science 269:682–685

    CAS  PubMed  Google Scholar 

  • Palombella VJ, Rando OJ, Goldberg AL, Maniatis T (1994) The ubiquitin-proteasome pathway is required for processing the NF-κB1 precusor protein and the activation of NF-κB. Cell 78:773–785

    PubMed  Google Scholar 

  • San Miguel JF, Blade Creixenti J, Garcia-Sanz R (1999) Treatment of multiple myeloma. Haematologica 84:36–58

    Google Scholar 

  • Schluter C, Duchrow M, Wohlenberg C, Becker MH, Key G, Flad HD, Gerdes J (1993) The cell proliferation-associated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins. J Cell Biol 123:513–522

    Google Scholar 

  • Schmid I, Cole SW, Korin YD, Zack JA, Giorgi JV (2000) Detection of cell cycle subcompartments by flow cytometric estimation of DNA-RNA content in combination with dual color immunofluorescence. Cytometry 39:108–116

    Article  CAS  PubMed  Google Scholar 

  • Shaughnessy J, Tian E, Sawyer J, Bumm K, Landes R, Badros A, Morris C, Tricot G, Epstein J, Barlogie B (2000) High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH. Blood 96:1505–1511

    CAS  PubMed  Google Scholar 

  • Taniguchi T, Endo H, Chikatsu N, Uchimaru K, Asano S, Fujita T, Nakahata T, Motokura T (1999) Expression of p21(Cip1/Waf1/Sdi1) and p27(Kip1) cyclin-dependent kinase inhibitors during human hematopoiesis. Blood 93:4167–4178

    CAS  PubMed  Google Scholar 

  • Traenckner EB, Wilk S, Baeuerle PA (1994) A proteasome inhibitor prevents activation of NF-κB and stabilizes a newly phosphorylated form of I κB-α that is still bound to NF-κB. EMBO 13:5433–5441

    CAS  Google Scholar 

  • Tricot G, Sawyer JR, Jagannath S, Desikan KR, Siegel D, Naucke S, Mattox S, Bracy D, Munshi N, Barlogie B (1997) Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants. J Clin Oncol 15:2659–2666

    CAS  PubMed  Google Scholar 

  • Tsurusawa M, Fujimoto T (1995) Cell cycle progression and phenotypic modification of Ki-67 antigen-negative G1- and G2-phase cells in phorbol ester-treated Molt-4 human leukemia cells. Cytometry 20:146–153

    CAS  PubMed  Google Scholar 

  • Wu Y, Luo H, Kanaan N, Wu J (2000) The proteasome controls the expression of a proliferation-associated nuclear antigen Ki-67. J Cell Biochem 76:596–604

    Article  CAS  PubMed  Google Scholar 

  • Yamada Y, Sugahara K, Tsuruda K, Nohda K, Mori N, Hata T, Maeda T, Hayashibara T, Joh T, Honda M, Tawara M, Tomonaga M, Miyazaki Y, Kamihira S (2000) Lactacystin activates FLICE (caspase 8) protease and induces apoptosis in Fas-resistant adult T-cell leukemia cell lines. Eur J Haematol 64:315–322

    Article  CAS  PubMed  Google Scholar 

  • Zojer N, Konigsberg R, Ackermann J, Fritz E, Dallinger S, Kromer E, Kaufmann H, Riedl L, Gisslinger H, Schreiber S, Heinz R, Ludwig H, Huber H, Drach J (2000) Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood 95:1925–1930

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology and Hematology, Universitätsklinikum Charité, Humboldt-Universität Berlin, 10098, Berlin, Germany

    Ivana Zavrski, Kathrin Niemöller, Christian Jakob, Ulrike Heider, Corinna Langelotz, Claudia Fleissner, Jan Eucker, Kurt Possinger & Orhan Sezer

  2. Institute of Immunology, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany

    Cord Naujokat

Authors
  1. Ivana Zavrski
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cord Naujokat
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kathrin Niemöller
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Christian Jakob
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ulrike Heider
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Corinna Langelotz
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Claudia Fleissner
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jan Eucker
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Kurt Possinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Orhan Sezer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Orhan Sezer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zavrski, I., Naujokat, C., Niemöller, K. et al. Proteasome inhibitors induce growth inhibition and apoptosis in myeloma cell lines and in human bone marrow myeloma cells irrespective of chromosome 13 deletion. J Cancer Res Clin Oncol 129, 383–391 (2003). https://doi.org/10.1007/s00432-003-0454-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-003-0454-6

Keywords

Search

Navigation